Navigation Links
Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
Date:5/16/2012

ND with R256.

ATS Poster Presentations
A Randomized, Placebo Controlled Trial of the Effect of an Inhaled SYK Inhibitor on Allergen Induced Airways Responses in Mild Asthma (R343)
May 21, 2012, 8:15AM – 4:30PM
Poster Session: B33 – ASTHMA THERAPY: NOVEL APPROACHES

Janus Kinase (JAK) 3 Inhibitor, R256, Attenuates Allergen-Induced Airway Hyperresponsiveness and Airway Inflammation in Mice
May 21, 2012, 8:15AM – 4:30PM
Poster Session: B33 – ASTHMA THERAPY: NOVEL APPROACHES

R256 Is a Potent and Selective IL13/4 Receptor Signaling Inhibitor That Reduces Inflammation In a Mouse Model of Chronic Asthma
May 21, 2012, 8:15AM – 4:30PM
Poster Session: B37 – NEW INSIGHTS INTO ASTHMA AND COPD TREATMENT

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with our partner AstraZeneca; R343, an inhaled SYK inhibitor that has completed Phase 1 clinical trials for asthma; R333, a topical JAK/SYK inhibitor for discoid lupus; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders.

This press release contains "forward-looking" statements, including, without limitation, statements related to Rigel's future product candidate pipeline and strategy.  Any statements contained in this pres
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  A Boston Scientific Corporation (NYSE: ... stent removability and preliminary long term stricture resolution ... the August issue of the peer-reviewed journal, Gastroenterology. ... is being conducted in 11 countries and five ... metal stents (FCSEMS) after extended indwell (i.e., up ...
(Date:8/29/2014)... -- Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, said today it ... Healthcare Conference on Wednesday, September 10. ... will provide an update on the company, beginning at ... Time).   A webcast of the presentation ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Peptide Cancer Therapeutics Market & Pipeline Insight 2014" ... methods developed to prevent and eradicate the prevalence of ... methods are confined to low specificity, safety and large ... look for a better solution. It has been discovered ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
... effectiveness for, patients, but Gilead Sciences and Merck and Co. ... ... LOS ANGELES, Sept. 10 AIDS Healthcare,Foundation (AHF) today called ... three-in-one, once daily lifesaving HIV,treatment, Atripla, in developing countries. When ...
... BioMosaics Inc., a cancer,biomarker development company, announced today ... products for the identification of Glypican-3,(GPC3) in human ... tests. This will,allow the GPC3 (Human Glypican-3) ELISA ... and the GPC3 (Human Glypican-3) Monoclonal Antibody (clone,1G12) ...
Cached Medicine Technology:Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations 2Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations 3BioMosaics' Glypican-3 Blood & Tissue Tests Receive CE Marking in Europe 2
(Date:9/1/2014)... September 02, 2014 NAPW ... Healthcare, LLC as a 2014 Professional Woman of the ... for leadership in office management. As the largest, most-recognized ... virtually every industry and profession, the National Association of ... over 600,000 members and nearly 300 Local Chapters. , ...
(Date:9/1/2014)... NAPW honors ... Orthopedics Pain Treatment & Cardiology, as a ... is recognized with this prestigious distinction for leadership ... organization of women in the country, spanning virtually ... Professional Women is a powerfully vibrant networking community ...
(Date:9/1/2014)... (PRWEB) September 02, 2014 Spine Team ... annual Reader’s Choice ‘Best of 2014’ award based on ... Northeast Tarrant County, Las Colinas & Coppell, Rockwall & ... would like to thank our patients and the residents ... Texas as LIVING magazine’s ‘Best of 2014’ in the ...
(Date:9/1/2014)... an innovative Washington State University study of deadly force ... black people. But when it came time to shoot, ... longer to pull the trigger against them than against ... the recent Journal of Experimental Criminology , grow ... disproportionate number of ethnic and racial minorities shot by ...
(Date:9/1/2014)... UWDress.com, a well-known wedding dress manufacturer and ... green bridesmaid dresses for its new and old ... company’s online category. What’s more, they are offered at ... offer is specially launched to celebrate the coming of ... have won great appreciation from worldwide clients. Now, the ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Victoria Smith, Office Manager at Apex Healthcare, LLC, a 2014 Professional Woman of the Year 2Health News:National Association of Professional Women Announces Laura Brinkley, Manager, Gibson Orthopedics Pain Treatment & Cardiology Clinic, a 2014 Professional Woman of the Year 2Health News:Spine Team Texas chosen in LIVING Magazine’s Reader’s Choice Awards 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 3Health News:2014 Lime Green Bridesmaid Dresses Offered At UWDress.com 2
... could help keep ones mind working.The study also found those ... fat have an increased risk of cognitive impairment during middle ... eat could play a role in your risk for dementia. ... with a lower risk of dementia. Researchers in the Netherlands ...
... in the recent issue of British Medical Journal say ... suicides and suicidal attempts.// ,Depression is characterized ... activities, low levels of self-esteem and confidence, and in ... and suicide. ,Clinical depression, also known as ...
... thyroid problem may have a lower risk of developing ... have shown that one of the circulating thyroid hormones ... mammary gland cells responded to thyroid hormones , population ... thyroid hormone and breast cancer. ,In a recent ...
... recent study researchers suggest that women drink wine to keep their ... wine is good for the heart. Although much of the research ... men, it is still not clear why moderate amounts of wine ... effects of wine on women’s hearts, the alcohol habits of 102 ...
... research conducted by Northwestern University about the effects of epidural ... analgesic given at the early stages of labor does not ... in their final term were observed for the study. All ... women who were given epidural in the early stages of ...
... onset wheezing is associated with high levels of allergies, ... the longest duration of wheezing also appear to have ... later in childhood end up with the same characteristics ... involved nearly 1,500 children born on the Isle of ...
Cached Medicine News:
A standard, durable and reliable indirect....
Designed to retain the desired curve during oral intubation....
Facilitates intubation of tracheal tubes....
SunGlide™ Stylette - Blue Neonatal. Use in 2.0 to 3.5mm tubes. 25/box....
Medicine Products: